



Bristol-Myers Squibb Australia Pty Ltd
ABN 33 004 333 322

PO Box 1080, Mt Waverley VIC 3149
Level 2, 4 Nexus Court, Mulgrave
Ph. 03 8523 4200
www.bmsa.com.au

24 November 2014

Dr Richard Chadwick
General Manager, Adjudication
Australian Competition and Consumer Commission
23 Marcus Clarke Street
Canberra ACT 2601

Dear Dr Chadwick

Re: Medicines Australia: Application for Revocation and Substitution (A91436-A91440)

Thank you for the opportunity to respond to the draft determination of the application. Bristol-Myers Squibb supports the transparency initiatives of Medicines Australia and is committed to achieve transparency goals. We support the views expressed in the Medicines Australia submission with respect to the ACCC conditions and comments. We suggest the ACCC consider that, since only member companies of Medicines Australia would engage Healthcare Professionals in this manner, implementation of the conditions will exacerbate the existing uneven playing field. In turn, this could undermine the public interest value as not all medicines companies that interact with Healthcare Professionals are signatories to Medicines Australia.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Anthony Mancini', written over a horizontal line.

Anthony Mancini
Managing Director Australia/New Zealand
Bristol-Myers Squibb Australia Pty Ltd